1-6 of 6
Hideo Yagita
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Paulino Tallón de Lara, Virginia Cecconi, Stefanie Hiltbrunner, Hideo Yagita, Martina Friess, Beata Bode, Isabelle Opitz, Bart Vrugt, Walter Weder, Paul Stolzmann, Emanuela Felley-Bosco, Rolf A. Stahel, Verena Tischler, Christian Britschgi, Davide Soldini, Maries van den Broek, Alessandra Curioni-Fontecedro
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (24): 6345–6354.
DOI: https://doi.org/10.1158/1078-0432.CCR-18-1231
Published: 13 December 2018
View article
PDF
Includes: Supplementary data
Journal Articles

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice

Elizabeth Ahern, Heidi Harjunpää, Deborah Barkauskas, Stacey Allen, Kazuyoshi Takeda, Hideo Yagita, David Wyld, William C. Dougall, Michele W.L. Teng, Mark J. Smyth
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5789–5801.
DOI: https://doi.org/10.1158/1078-0432.CCR-17-0606
Published: 01 October 2017
View article
PDF
Includes: Supplementary data
Journal Articles

Epigenetic Modulation Enhances the Therapeutic Effect of Anti–IL-13Rα2 Antibody in Human Mesothelioma Xenografts

Makoto Takenouchi, Sachie Hirai, Naoya Sakuragi, Hideo Yagita, Hirofumi Hamada, Kazunori Kato
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (9): 2819–2829.
DOI: https://doi.org/10.1158/1078-0432.CCR-10-2986
Published: 01 May 2011
View article
PDF
Journal Articles

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Takeo Nomi, Masayuki Sho, Takahiro Akahori, Kaoru Hamada, Atsushi Kubo, Hiromichi Kanehiro, Shinji Nakamura, Koji Enomoto, Hideo Yagita, Miyuki Azuma, Yoshiyuki Nakajima
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2151–2157.
DOI: https://doi.org/10.1158/1078-0432.CCR-06-2746
Published: 02 April 2007
View article
PDF
Journal Articles

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

Yuichiro Ohigashi, Masayuki Sho, Yukishige Yamada, Yoshikazu Tsurui, Kaoru Hamada, Naoya Ikeda, Takashi Mizuno, Ryo Yoriki, Hisanori Kashizuka, Katsunari Yane, Fumihiko Tsushima, Noriko Otsuki, Hideo Yagita, Miyuki Azuma, Yoshiyuki Nakajima
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 2947–2953.
DOI: https://doi.org/10.1158/1078-0432.CCR-04-1469
Published: 18 April 2005
View article
PDF
Journal Articles

Partial Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/TRAIL Receptor Pathway to Antitumor Effects of Interferon-α/5-Fluorouracil against Hepatocellular Carcinoma

Tameyoshi Yamamoto, Hiroaki Nagano, Masato Sakon, Hisashi Wada, Hidetoshi Eguchi, Motoi Kondo, Bazarragchaa Damdinsuren, Hideo Ota, Masato Nakamura, Hiroshi Wada, Shigeru Marubashi, Atsushi Miyamoto, Keizo Dono, Koji Umeshita, Shoji Nakamori, Hideo Yagita, Morito Monden
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (23): 7884–7895.
DOI: https://doi.org/10.1158/1078-0432.CCR-04-0794
Published: 07 December 2004
View article
PDF